Of the announcement, I highlighted three items that are really good. Equity finance will cause a bit of pain but I guess that is a quick way to fund the technology - the question really is by what price and dilution? Japan pathway is the bit that is promising.
Unfortunately, 18 months to complete phase 3 is too long for most hotcopperites people as most has an investment period of 7 days. 30 days is normally considered long-term.
MESOBLAST PROVIDES UPDATE ON GLOBAL HEART FAILURE PROGRAM
Key points:
- Mesoblast regains worldwide rights to cardiovascular field for its cell therapy platform
- Lead product candidate in cardiovascular portfolio is MPC-150-IM for heart failure, with multibillion dollar blockbuster potential and no financial consideration to Teva Pharmaceutical Industries Ltd
- Independent Data Monitoring Committee recommended continuation of the 600-patient heart failure trial without modification after clinical data review of first 175 patients
- Mesoblast aims to complete the Phase 3 heart failure trial, almost 40% recruited, within eighteen months
- To meet the program’s remaining funding requirements, Mesoblast has been offered an equity finance facility
- FDA approval has been obtained to incorporate into the heart failure program a widely-used second catheter delivery system which is likely to result in accelerated recruitment and provide a commercial distribution channel
- Japan conditional approval pathway provides potential early revenue opportunity
- Mesoblast now has unencumbered rights to partner with a leading cardiovascular company with a commitment to heart failure product commercialization
- Forums
- ASX - By Stock
- Ann: Update on Global Heart Failure Program-MSB.AX
Of the announcement, I highlighted three items that are really...
-
- There are more pages in this discussion • 121 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B |
Open | High | Low | Value | Volume |
$1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 43856 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.11 | 66000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 52505 | 1.100 |
1 | 4552 | 1.095 |
3 | 60574 | 1.090 |
3 | 31716 | 1.085 |
2 | 14000 | 1.080 |
Price($) | Vol. | No. |
---|---|---|
1.110 | 66000 | 1 |
1.115 | 80808 | 1 |
1.120 | 88882 | 4 |
1.125 | 74996 | 5 |
1.130 | 111884 | 6 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |